Recent Updates
Recently added Catalysts

Testosterone

Phase 3

Hypogonadism | Small molecule | Endocrine |Eli Lilly and Company|Last Updated: Dec 28, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment715
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01816295A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and EnergyPHASE3 COMPLETED 715May 1, 2013Apr 1, 2015Dec 28, 201585 United States, Argentina +7
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12
Week 12

Normal range for total serum testosterone was defined as 300 to 1050 nanograms per deciliter (ng/dL).

Secondary Endpoints
Change From Baseline to Week 12 in Sexual Arousal, Interest, and Drive (SAID) Scale Scores
Baseline, Week 12
Change From Baseline to Week 12 in Hypogonadism Energy Diary (HED) Scores
Baseline, Week 12
Number of Participants With Prostate Specific Antigen (PSA) >4 Nanogram/Milliliter (ng/mL)
Double Blind Baseline, Week 12, Open Label Baseline, Week 36
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Placebo SolutionPLACEBO_COMPARATORPlacebo Solution applied topically once daily for 12 weeks.
Testosterone SolutionEXPERIMENTALTestosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
Interventions
NameTypeDescription
Testosterone SolutionDRUGAdministered topically to axillae.
Placebo SolutionDRUGAdministered topically to axillae.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexMALE
Healthy VolunteersNo
Study Sites85

Inclusion Criteria: * Total testosterone level \<300 nanogram per deciliter (ng/dL) \[10.4 nanomole per Liter (nmol/L)\] at each of 2 screening visits * At least 1 symptom of testosterone deficiency, which must include decreased energy or decreased sexual drive * Prostate Specific Antigen (PSA) \<4...

Countries:United StatesArgentinaCanadaGermanyItalyPuerto RicoSouth KoreaSpainUnited Kingdom
Unlock Eligibility Criteria